cardiovascular disease

Alameda, California | April 13, 2026 Penumbra, Inc. has announced compelling 90-day results from the STORM-PE randomized controlled trial,...

April 7, 2026 — Global HeartFocus, developed by DESKi, in partnership with Inteleos®, has launched the first AI-enabled cardiac...

MOUNTAIN VIEW, Calif., April 07, 2026 AliveCor Inc., a global leader in AI-powered cardiology solutions, has announced the regulatory...

CAMBRIDGE, Mass., April 8, 2026 Anumana, Inc. has received U.S. FDA clearance for its ECG-AI™ algorithm designed to detect...

Waltham, Massachusetts, USA, April 6, 2026 Health Canada Approval Marks Key Clinical Milestone In a significant development for cardiovascular...

RESEARCH TRIANGLE PARK, N.C., USA, March 31, 2026 AskBio, a wholly owned and independently operated subsidiary of Bayer AG,...

South San Francisco, California — March 5, 2026 Tenaya Therapeutics and Alnylam Pharmaceuticals have announced a major research collaboration...

December 16, 2025 – Cambridge, Massachusetts — Atom Therapeutics has announced the initiation of a multi-regional Phase 2 clinical...

Pittsburgh, PA & Toronto, ON — November 26, 2025. Sharp Therapeutics Corp. has released its condensed interim consolidated financial...

CALGARY, Alberta — November 26, 2025. Hemostemix Inc. has taken a major step in its global clinical-commercial expansion, announcing...